NEW YORK (GenomeWeb) – Israeli RNAi drug developer Silenseed has filed to go public in the US, looking to raise around $36.4 million to support the continued clinical development of its oncology pipeline and the implantable delivery system that enables it.

According to Silenseed CEO and Co-founder Amotz Shemi, the company had been exploring opportunities to raise the money needed to conduct the clinical testing of its flagship pancreatic cancer treatment, which recently completed a Phase I study, eventually deciding to pursue an initial public offering on the Nasdaq.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.